Injectable Drug Delivery Size And Trends

The global injectable drug delivery market size is valued to be US$ 780.0 billion in 2025, reaching US$ 1,410.1 billion by 2032 and exhibiting a CAGR of 8.8% during the forecast period 2025-2032.

Recent Market Trends

• Microneedle-based injectables are gaining traction across clinical setting, enabling virtually painless transdermal delivery of biologics and vaccines, especially in chronic care management and pediatric immunization.
• Dual-chamber prefilled syringes (DCPFS) are transforming stability-sensitive drug administration by enabling instant reconstitution of lyophilized compounds at point-of-care.
• Wearable injectors are redefining patient-centric delivery, particularly in oncology and autoimmune therapies, with leading-edge models facilitating controlled subcutaneous infusion of high-viscosity biologics over extended durations.
• Connected auto-injectors are incorporating Bluetooth and AI-based adherence tracking, feeding the growing adoption of remote patient monitoring and personalized dosing routines.
• The noticeable rise in GLP-1 agonists for obesity and Type 2 diabetes treatment is escalating the demand for high-volume, user-friendly injectable pens with customizable dose delivery.

Injectable Drug Delivery Market in the News

• June 2025: Sanofi announced the development of a subcutaneous (SC) version of its multiple myeloma drug Sarclisa, delivered via an investigational on-body injector (OBI) called enFuse from Enable Injections. This hands-free device uses a hidden, retractable needle thinner than typical SC needles, improving patient comfort and reducing administration time compared to the traditional intravenous (IV) infusion.
• May 2025: Novo Holdings, a global life sciences investor, announced an investment in SCHOTT Poonawalla, which is India’s leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals. The company is a joint venture between SCHOTT Pharma AG and the Serum Institute of India, with operations including three manufacturing facilities in India and a capacity of over 3 billion units annually. This investment by Novo Holdings, alongside TPG Growth, represents Novo Holdings' first foray into India's medtech manufacturing sector.
• April 2025: Ypsomed announced the sale of its diabetes care business, including subsidiaries and patch pump development activities, to TecMed AG for up to CHF 420 million (approximately US$ 517.7 million). This transaction marks Ypsomed's strategic shift to focus exclusively on the subcutaneous self-injection market for pharmaceutical and biotech companies. TecMed will combine Ypsomed’s mylife Loop tube pump system with its own patch pump program to create a global leader in innovative insulin infusion systems.

Segmental Analysis

In the product segment, insulin pens are expected to account for 53% of the injectable drug delivery market share in 2025. Their growing popularity is owing to the convenience, portability, and dosing precision they offer, making these pens especially helpful for people with mobility or vision challenges. Unlike the traditional vial-and-syringe system, insulin pens virtually eliminate the practical barriers to regular insulin use, because of which they are increasingly seen as the most favored option in diabetes care. Auto injectors are also gathering momentum, simultaneously, especially in the biologics space. Designed for ease of self-administration, they offer a needle-free or concealed-needle experience that enhances patient comfort and reduces the probability of dosing errors.

On the usage front, disposable injectors are set to dominate the revenue share in 2025, as their single-use property minimizes the risk of contamination, making them ideal for both hospitals and home care. These instruments are find widening application for subcutaneous and intramuscular therapies. The demand for reusable injectors is also steadily growing, on account of their lower long-term cost, environmental benefits, and suitability for frequent use, such as in cases of insulin or hormone therapies.

Regional Analysis

North America is anticipated to command a 40% share of the injectable drug delivery market in 2025. This dominant positon of the region is largely fueled by the increasing demand for self-administered therapies aimed at managing chronic illnesses such as diabetes, cancer, and autoimmune disorders. The United States is spearheading the regional expansion of the market, with biologic drugs now representing over 60% of the country’s top-grossing pharmaceuticals. The U.S. FDA has been playing a pivotal role in fostering pharma-tech partnerships. Notable innovations, such as Eli Lilly’s Tempo Smart Button and Amgen’s on-body injector systems for Neulasta and Enbrel, are making wearable injectors and smart delivery platforms a de facto part of biologics treatment options.

On the other side of the Atlantic, the market is benefiting from a heightened uptake of biologic drug delivery systems and home-based self-injection devices across Europe. Healthcare facilities in Germany, the U.K., France, and Italy are readily embracing next-gen technologies such as prefilled syringes, auto-injectors, microneedles, and wearable injection systems, reflecting a steady shift toward decentralized care. In Asia Pacific, market players are looking at highly lucrative opportunities driven by expanding access to healthcare, improving governmental support for chronic disease management, and increasing investments in injectable drug manufacturing, especially India.

Industry Players

With pharmaceutical giants, medical device manufacturers, and agile biotech startups forming strategic alliances to develop innovative drug-device combinations, especially for chronic disease therapies in oncology and diabetes, the competitive landscape of the global injectable drug delivery market is becoming intense and vibrant. A growing focus on patient-centric injectable platforms is boosting treatment adherence by making self-administration safer, simpler, and more precise. Industry participants are racing to deliver precision-engineered injection technologies that enable subcutaneous and intramuscular dosing for biologics and biosimilars with minimal user error. Leading companies such as BD, Gerresheimer, West Pharmaceutical Services, SHL Medical, Ypsomed, and Bespak are at the forefront, investing heavily in next-gen injector formats, smart tracking features, and device miniaturization.